Abstract Purpose of Review Due to lack of pediatric-specific data, the management of
chronic myeloid leukemia (CML) in pediatric, adolescents, and young adults is guided by …

The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the
advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second …

Background While impressive gains in childhood cancer survival have been reported both in
Canada and internationally, it has been almost 15 years since the last comprehensive …

During the past decade, the outcomes of pediatric patients with acute myeloid leukemia
(AML) have plateaued with 5‐year event‐free survival (EFS) and overall survival (OS) of …

Tyrosine kinase inhibitors (TKIs) have significantly changed the treatment of chronic myeloid
leukemia (CML) and improved outcomes for patients with CML in chronic phase (CML-CP) …

The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm of
chronic myeloid leukemia (CML), leading to a dramatic improvement of the outcome of CML …

The phase 2, open-label study (DIALOG) of nilotinib in pediatric patients with Philadelphia
chromosome-positive chronic myelogenous leukemia (CML) met its coprimary end points …

The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children
compared to adults. At younger age, anemia appears to be frequent at diagnosis, but its …

Simple Summary The low incidence (1: 1,000,000) of chronic myeloid leukemia (CML) in the
first two decades of life presents an obstacle to accumulation of pediatric experience and …

Abstract Purpose of Review Chronic myelogenous leukemia (CML) is rare in children,
requiring extrapolation from treatment of adults. In this review, we explore similarities and …